Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate

Tusamitamab ravtansine (SAR408701) is an antibody-drug conjugate (ADC), combining a humanized monoclonal antibody (IgG1) targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and a potent cytotoxic maytansinoid derivative, DM4, inhibiting microtubule assembly. SAR408701 is cu...

Descripción completa

Detalles Bibliográficos
Autores principales: Pouzin, Clemence, Gibiansky, Leonid, Fagniez, Nathalie, Chadjaa, Mustapha, Tod, Michel, Nguyen, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098589/
https://www.ncbi.nlm.nih.gov/pubmed/35166967
http://dx.doi.org/10.1007/s10928-021-09799-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098589/
https://www.ncbi.nlm.nih.gov/pubmed/35166967
http://dx.doi.org/10.1007/s10928-021-09799-0

Ejemplares similares